Evidence map›Paper›PMID 27590822›Full record

ArticleApplied and environmental microbiology2016

Lack of Overt Genome Reduction in the Bryostatin-Producing Bryozoan Symbiont "Candidatus Endobugula sertula".

Ian J Miller, Niti Vanee, Stephen S Fong, Grace E Lim-Fong, Jason C Kwan

Open access · bronzeAbstract read
In one paragraph

Article in Applied and environmental microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The genome sequence of the ruby bryozoan,Wellcome open research · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Natural Products as a Foundation for Drug Discovery.Current protocols in pharmacology · 2019
    Review
  16. Article
  17. Article
  18. Emerging evolutionary paradigms in antibiotic discovery.Journal of industrial microbiology & biotechnology · 2019
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ian J MillerPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Niti VaneeDepartment of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, Virginia, USA.
Stephen S FongDepartment of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, Virginia, USA.
Grace E Lim-FongDepartment of Biology, Randolph-Macon College, Ashland, Virginia, USA.
Jason C KwanPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin, USA jason.kwan@wisc.edu.ORCID 0000-0001-9933-1536
University of Wisconsin–Madison · USVirginia Commonwealth University · USRandolph–Macon College · US

Funding

Microbial-ecology guided discovery of non-traditional therapeutics that limit resistanceR21AI121704 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KWAN, JASON CHRISTOPHER · 2016 to 2017
$406k
NIAID NIH HHS R21 AI121704
6 · The paper itself

Abstract

The uncultured bacterial symbiont "Candidatus Endobugula sertula" is known to produce cytotoxic compounds called bryostatins, which protect the larvae of its host, Bugula neritina The symbiont has never been successfully cultured, and it was thought that its genome might be significantly reduced. Here, we took a shotgun metagenomics and metatranscriptomics approach to assemble and characterize the genome of "Ca Endobugula sertula." We found that it had specific metabolic deficiencies in the biosynthesis of certain amino acids but few other signs of genome degradation, such as small size, abundant pseudogenes, and low coding density. We also identified homologs to genes associated with insect pathogenesis in other gammaproteobacteria, and these genes may be involved in host-symbiont interactions and vertical transmission. Metatranscriptomics revealed that these genes were highly expressed in a reproductive host, along with bry genes for the biosynthesis of bryostatins. We identified two new putative bry genes fragmented from the main bry operon, accounting for previously missing enzymatic functions in the pathway. We also determined that a gene previously assigned to the pathway, bryS, is not expressed in reproductive tissue, suggesting that it is not involved in the production of bryostatins. Our findings suggest that "Ca Endobugula sertula" may be able to live outside the host if its metabolic deficiencies are alleviated by medium components, which is consistent with recent findings that it may be possible for "Ca Endobugula sertula" to be transmitted horizontally. IMPORTANCE: The bryostatins are potent protein kinase C activators that have been evaluated in clinical trials for a number of indications, including cancer and Alzheimer's disease. There is, therefore, considerable interest in securing a renewable supply of these compounds, which is currently only possible through aquaculture of Bugula neritina and total chemical synthesis. However, these approaches are labor-intensive and low-yielding and thus preclude the use of bryostatins as a viable therapeutic agent. Our genome assembly and transcriptome analysis for "Ca Endobugula sertula" shed light on the metabolism of this symbiont, potentially aiding isolation and culturing efforts. Our identification of additional bry genes may also facilitate efforts to express the complete pathway heterologously.

Indexed as

Genome, BacterialSymbiosisAnimalsBryostatinsBryozoaGammaproteobacteriaGene Expression ProfilingLarvaMetagenomicsPhylogenyPseudogenesbryostatin 1Bryostatins

Identifiers

PMID27590822
PMCPMC5086551
OpenAlexW2513652105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.